Search Result

Results for "

glutaminase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Glutaminase (29) Apoptosis (2) Autophagy (3) Biochemical Assay Reagents (2) Drug Derivative (1) Endogenous Metabolite (11) Environmental Pollutants (11) ERK (1) Ferroptosis (11) HIF/HIF Prolyl-Hydroxylase (12) Isotope-Labeled Compounds (10) JNK (1) mGluR (11) mTOR (12) NF-κB (12) Phosphatase (1) Ras (1) Reactive Oxygen Species (ROS) (2) Reference Standards (4) STAT (12)
By Research Areas:	Cancer (26) Cardiovascular Disease (12) Inflammation/Immunology (17) Metabolic Disease (14) Neurological Disease (15)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

GMP Molecules

Targets Recommended: Glutaminase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12248

Telaglenastat Maximum Cited Publications 104 Publications Verification CB-839	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and *GAC (glutaminase* C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy** and has antitumor activity .

HY-12683

BPTES 60+ Cited Publications	Glutaminase	Cancer
BPTES is an allosteric and selective *glutaminase* inhibitor with an IC₅₀ of 0.16 μM.

HY-N0390S1

L-Glutamine-13C5 Maximum Cited Publications 9 Publications Verification L-Glutamic acid 5-amide-¹³C₅	Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine- ¹³C₅ is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-12682

Glutaminase C-IN-1 10+ Cited Publications Compound 968	Glutaminase	Cancer
Glutaminase C-IN-1 (Compound 968) is an allosteric inhibitor of Glutaminase C that inhibits cancer cell growth without affecting their normal cellular counterparts .

HY-122218

JHU-083 5+ Cited Publications	Glutaminase	Neurological Disease
JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective *glutaminase* antagonist. JHU-083 blocks glutaminase activity in brain CD11b ⁺ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals .

HY-N0390S

L-Glutamine-15N 3 Publications Verification L-Glutamic acid 5-amide-¹⁵N	Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine- ¹⁵N is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S8

L-Glutamine-15N2 1 Publications Verification L-Glutamic acid 5-amide-¹⁵N₂	Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine- ¹⁵N₂ is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S9

L-Glutamine-15N-1 3 Publications Verification L-Glutamic acid 5-amide-¹⁵N-1	Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine- ¹⁵N-1 is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S2

L-Glutamine-d5 1 Publications Verification L-Glutamic acid 5-amide-d₅	Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine-d₅ is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S6

L-Glutamine-13C5,15N2 L-Glutamic acid 5-amide-¹³C₅,¹⁵N₂	Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine- ¹³C₅, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390R

L-Glutamine (Standard) 25+ Cited Publications L-Glutamic acid 5-amide (Standard)	Reference Standards mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine (Standard) is the analytical standard of L-Glutamine (HY-N0390). This product is intended for research and analytical applications. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-114334

Glutaminase-IN-1 1 Publications Verification CB839 derivative	Glutaminase	Cancer
Glutaminase-IN-1 (CB839 derivative), a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC₅₀ of 1 nM. Glutaminase-IN-1 (CB839 derivative) shows improved cellular uptake and antitumor activity.

HY-103671

IPN60090	Glutaminase	Inflammation/Immunology Cancer
IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers .

HY-136704

GLS1 Inhibitor-1	Glutaminase	Cancer
GLS1 Inhibitor-1 (Compound 27) is an orally active inhibitor for glutaminase 1 (GLS1) with an IC₅₀ of 0.021 μM. GLS1 Inhibitor-1 inhibits the proliferation of PC-3 with an IC₅₀ of 0.3 nM. GLS1 Inhibitor-1 exhibits antitumor efficacy against NCI-H1703 with GI₅₀ of 0.011 μM. GLS1 Inhibitor-1 exhibits moderate pharmacokinetic characteristics .

HY-103671A

IPN60090 dihydrochloride	Glutaminase	Inflammation/Immunology Cancer
IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers .

HY-P2760

*Glutaminase* GLS	Biochemical Assay Reagents Glutaminase	Cancer
Glutaminase is a metabolic enzyme. Glutaminase catalyzes the hydrolysis of glutamine to glutamate. Glutaminase isoenzymes are encoded by Gls and Gls2 genes. Proteins GLS and GLS2 have different kinetic, immunologic, and molecular characteristics. Glutaminase can be used in the research of cancer .

HY-79583

Glutaminase-IN-3 1 Publications Verification	Glutaminase	Cancer
Glutaminase-IN-3 (compound 657) is a potent *glutaminase* inhibitor with an IC₅₀ of 0.24 μM for Glutaminase 1 (GLS1). Glutaminase-IN-3 is extracted from patent WO2014089048A1, compound 657 .

HY-N0390S5

L-Glutamine-1-13C 1 Publications Verification L-Glutamic acid 5-amide-1-¹³C	Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine-1- ¹³C is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S4

L-Glutamine-5-13C L-Glutamic acid 5-amide-5-¹³C	Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine-5- ¹³C is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-W006187

2-Amino-2-(p-tolyl)acetic acid (Rac)-H-Phg(4-Me)-OH	Glutaminase	Cancer
2-Amino-2-(p-tolyl)acetic acid is used for optimizing azide skeleton, and is the intermediate in the synthesis of 1,3, 4-thiadiazole compounds. 1,3,4-thiadiazole compounds exhibit potential anti-cancer activity, and inhibit glutaminase (GLSI) .

HY-12248R

Telaglenastat (Standard) CB-839 (Standard)	Glutaminase Autophagy Reference Standards	Cancer
Telaglenastat (Standard) is the analytical standard of Telaglenastat. This product is intended for research and analytical applications. Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .

HY-N0390S3

L-Glutamine-13C5,15N2,d5 L-Glutamic acid 5-amide-¹³C₅,¹⁵N₂,d₅	Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine- ¹³C₅, ¹⁵N₂,d₅ is the deuterium, ¹³C-, and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-12248A

Telaglenastat hydrochloride CB-839 hydrochloride	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and *GAC (glutaminase* C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy** and has antitumor activity .

HY-151434

GLS1 Inhibitor-6	Glutaminase Apoptosis	Cancer
GLS1 Inhibitor-6 (Compound 24y) is an orally active, potent and selective glutaminase 1 (GLS1) inhibitor (IC₅₀=68 nM), shows 220-fold selectivity for GLS2. GLS1 Inhibitor-6 shows good anti-tumor activity, antitumor cell proliferation activity and induces apoptosis .

HY-W353728

N-Carbobenzoxytyramine N-CBZ-Tyramine	Glutaminase	Metabolic Disease
N-Carbobenzoxytyramine (N-CBZ-Tyramine), a carbobenzoxy derivatives of amino acid, is a competitive inhibitor of *glutaminase* activity .

HY-149602

Glutaminase C-IN-2	Glutaminase Reactive Oxygen Species (ROS)	Cancer
Glutaminase C-IN-2 (compound 11) is glutaminase C (GAC) allosteric inhibitor with an IC₅₀ of 10.64 nM. Glutaminase C-IN-2 regulates the cellular metabolite, thereby increasing reactive oxygen species (ROS) by blocking glutamine metabolism. Glutaminase C-IN-2 has anticancer effects .

HY-12683R

BPTES (Standard)	Glutaminase	Cancer
BPTES (Standard) is the analytical standard of BPTES. This product is intended for research and analytical applications. BPTES is an allosteric and selective glutaminase inhibitor with an IC50 of 0.16 μM.

HY-119377

UPGL00004	Glutaminase	Cancer
UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC₅₀=29 nM; K_d=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines .

HY-152207

LWG-301	Glutaminase Apoptosis	Cancer
LWG-301 is an allosteric inhibitor of Glutaminase 1 (GLS1) with an IC₅₀ value of 7 nM. LWG-301 significantly block glutamine metabolism, increases intracellular ROS, thus induces apoptosis. LWG-301 exhibits moderate antitumor effects in HCT116 xenograft model .

HY-146658

Glutaminase-IN-4	Glutaminase	Cancer
Glutaminase-IN-4 (compound 2a) is a glutaminase (GLS) inhibitor with an IC₅₀ of 2.3 μM .

HY-114929

THDP17	Glutaminase	Neurological Disease
THDP17 is an orally active *glutaminase* inhibitor. THDP17 decreases ammonia production through glutaminase inhibition .

HY-N2916

Barbinervic acid	Glutaminase	Neurological Disease
Barbinervic acid is a *glutaminase* inhibitor with an IC₅₀ of 14 μM. Barbinervic acid can be used for the study of neurodegenerative diseases .

HY-148241

A-446	Glutaminase	Cancer
A-446, a chemical probe, is a potent glutaminase (GLS) inhibitor with an IC₅₀ value of 31 nM .

HY-174211

JNK-IN-23	JNK	Cancer
JNK-IN-23 (Compound K12) is an inhibitor of JNK. JNK-IN-23 inhibits the proliferation of MDA-MB-231 (GIC₅₀: 30 nM). JNK-IN-23 blocks TNBC metastatic growth in vivo. JNK-IN-23 inhibits the growth of lung metastases by dual targeting of glutaminase-1 (GLS) and pyruvate dehydrogenase complex (PDHC) .

HY-155138

GLS1 Inhibitor-7	Glutaminase	Metabolic Disease Cancer
GLS1 Inhibitor-7 (compound 4d) is a GLS1 inhibitor (IC₅₀=46.7 μM), with potential anti-cancer, anti-aging and anti-obesity properties .

HY-158378

Trivalent hydroxyarsinothricn R-AST-OH	Glutaminase	Cancer
Trivalent hydroxyarsinothricn (R-AST-OH) is a covalent and irreversible *kidney-type glutaminase* (KGA)** inhibitor. Trivalent hydroxyarsinothricn binds to the glutamine binding site and forms a covalent bond with an active site cysteine residue. Trivalent hydroxyarsinothricn selectively kills triple-negative breast cancer (TNBC) cells and is not cytotoxic to the control cell line. KGA is the enzyme that controls glutamine metabolism and is correlated with tumor malignancy .

HY-178978

α,δ-NAG	Drug Derivative Phosphatase ERK Ras	Inflammation/Immunology
α,δ-NAG is an orally active glutaminase-resistant less-hydrolyzable L-Glutamine derivative. α,δ-NAG is a G protein-coupled receptor (GPCR) allosteric modulator. α,δ-NAG suppresses neutrophilic airway inflammation by activating the GPCR/ERK/MKP-1 pathway. α,δ-NAG can be used for the researches of inflammation and immunology, such as asthma .

HY-180241

Glutaminase C-IN-3	Glutaminase Reactive Oxygen Species (ROS)	Cancer
Glutaminase C-IN-3 is a potent allosteric inhibitor of Glutaminase C (GAC) with an EC₅₀ of 116 nM. Glutaminase C-IN-3 regulates cellular metabolites and increases reactive oxygen species (ROS) production by blocking glutamine metabolism. Glutaminase C-IN-3 exhibits strong antitumor activity in an A549 xenograft mouse model. Glutaminase C-IN-3 can be used for the research of non-small cell lung cancer (NSCLC) .

HY-N0390S7

L-Glutamine-15N2,d5 L-Glutamic acid 5-amide-¹⁵N₂,d₅	Isotope-Labeled Compounds mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine- ¹⁵N₂,d₅ is the deuterium and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-103671AR

IPN60090 dihydrochloride (Standard)	Reference Standards Glutaminase	Inflammation/Immunology Cancer
IPN60090 dihydrochloride (Standard) is the analytical standard of IPN60090 dihydrochloride (HY-103671A). This product is intended for research and analytical applications. IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers .

HY-103671R

IPN60090 (Standard)	Reference Standards Glutaminase	Inflammation/Immunology Cancer
IPN60090 (Standard) is the analytical standard of IPN60090 (HY-103671). This product is intended for research and analytical applications. IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers .

HY-181890

TRG-192	Glutaminase	Cancer
TRG-192 is a potent and selective glutaminase (GLS) inhibitor with an IC₅₀ of 68 nM. TRG-192 inhibits intracellular glutamate levels. TRG-192 is applicable to related research on non-small cell lung cancer .

HY-N0390G

L-Glutamine	mTOR NF-κB STAT HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-E71341

γ-Glutamyl-γ-aminobutyrate hydrolase	Biochemical Assay Reagents	Others
γ-Glutamyl-γ-aminobutyrate hydrolase (EC 3.5.1.94), forms part of a putrescine-utilizing pathway in Escherichia coli, in which it has been hypothesized that putrescine is first glutamylated to form γ-Glutamylputrescine, which is oxidized to 4-(γ-Glutamylamino) butanal and then to 4-(γ-Glutamylamino) butanoate. The enzyme can also catalyse the reactions of EC 3.5.1.35 (D-glutaminase) and EC 3.5.1.65 (theanine hydrolase) .

Cat. No.	Product Name

HY-L064

Glutamine Metabolism Compound Library	1,690 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 1,690 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

1,690 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 1,690 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

HY-L189

Amino Acid Metabolism Compound Library

335 compounds

Amino acids, as one of the most fundamental organic compounds in living organisms, serve not only as the basic building blocks of proteins but also but also undertake the functions of energy supply, neurotransmitter synthesis, and maintenance of internal environment stability.Amino acid metabolic enzymes are a class of enzymes involved in the metabolic processes of amino acids, catalyzing their synthesis, breakdown, transformation, and interactions with other metabolic pathways. Abnormalities in amino acid metabolic enzymes can lead to various metabolic diseases, such as phenylketonuria and hyperammonemia, etc. Therefore, actively exploring and regulating the processes of amino acid metabolism is crucial for the development of drugs related to these diseases.

MCE designs a unique collection of 335 small molecules target amino acid metabolizing enzymes, which is an important tool for studying studying amino acid metabolism processes or metabolism-related drug development.

HY-L239

Steroid Hormones Library

70 compounds

Steroid hormones (also known as steroidal hormones) are a class of tetracyclic aliphatic hydrocarbon compounds derived from cholesterol. Typical representatives of steroid hormones include cortisol, aldosterone, testosterone, estradiol, among others. These hormones serve diverse regulatory functions within the body. For instance, aldosterone helps maintain the homeostasis of extracellular fluid volume and circulating blood volume; testosterone and estradiol primarily promote the development and maturation of male and female reproductive organs and regulate reproductive functions.

MCE designs a unique collection of 70 steroid hormones. This library can be used for research related to metabolic or immune diseases, investigations into the mechanisms of action of nuclear receptor signaling pathways, as well as identification and quantitative analysis in metabolomics studies.

Cat. No.	Product Name	Type

HY-N0390G

L-Glutamine

Fluorescent Dyes

L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

Cat. No.	Product Name	Type

HY-N0390G

L-Glutamine

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-W006187

2-Amino-2-(p-tolyl)acetic acid (Rac)-H-Phg(4-Me)-OH	Glutaminase	Cancer
2-Amino-2-(p-tolyl)acetic acid is used for optimizing azide skeleton, and is the intermediate in the synthesis of 1,3, 4-thiadiazole compounds. 1,3,4-thiadiazole compounds exhibit potential anti-cancer activity, and inhibit glutaminase (GLSI) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0390R

L-Glutamine (Standard) 25+ Cited Publications L-Glutamic acid 5-amide (Standard)	Structural Classification Human Gut Microbiota Metabolites Immune System Disorder Microorganisms Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer Source Classification	Reference Standards mGluR Ferroptosis Environmental Pollutants Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase mTOR STAT NF-κB
L-Glutamine (Standard) is the analytical standard of L-Glutamine (HY-N0390). This product is intended for research and analytical applications. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N2916

Barbinervic acid	Ketones, Aldehydes, Acids Rubiaceae Mitragyna inermis (Willd.) Kuntze Plants Source Classification	Glutaminase
Barbinervic acid is a *glutaminase* inhibitor with an IC₅₀ of 14 μM. Barbinervic acid can be used for the study of neurodegenerative diseases .

Cat. No.	Product Name	Chemical Structure

HY-N0390S1

L-Glutamine-13C5

Maximum Cited Publications

9 Publications Verification

L-Glutamine- ¹³C₅ is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S

L-Glutamine-15N

3 Publications Verification

L-Glutamine- ¹⁵N is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S8

L-Glutamine-15N2

1 Publications Verification

L-Glutamine- ¹⁵N₂ is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S9

L-Glutamine-15N-1

3 Publications Verification

L-Glutamine- ¹⁵N-1 is the ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S2

L-Glutamine-d5

1 Publications Verification

L-Glutamine-d₅ is the deuterium labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S6

L-Glutamine-13C5,15N2

L-Glutamine- ¹³C₅, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S5

L-Glutamine-1-13C

1 Publications Verification

L-Glutamine-1- ¹³C is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S4

L-Glutamine-5-13C

L-Glutamine-5- ¹³C is the ¹³C-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S3

L-Glutamine-13C5,15N2,d5

L-Glutamine- ¹³C₅, ¹⁵N₂,d₅ is the deuterium, ¹³C-, and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

HY-N0390S7

L-Glutamine-15N2,d5

L-Glutamine- ¹⁵N₂,d₅ is the deuterium and ¹⁵N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

Host:	Mouse (1) Rabbit (4)
Reactivity:	Human (5) Rat (5) Mouse (5)
Application:	IHC-P (3) ICC/IF (3) IP (3) WB (5) FC (1) ELISA (1)
Isotype:	IgG (4) IgG1 (1)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (4) Recombinant (2)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87274

	GLS2 Antibody (YA6957) breast cell glutaminase antibody; GA antibody; GLS antibody; Gls2 antibody; GLSL_HUMAN antibody; glutaminase 2 (liver mitochondrial) antibody; glutaminase 2 antibody; glutaminase GA antibody; glutaminase I antibody; glutaminase liver isoform antibody	WB, IHC-P	Human, Mouse, Rat
	GLS2 Antibody (YA6957) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GLS2.

HY-P80690

	Glutaminase Antibody (YA406) glutaminase kidney isoform; GLS; GLS1; KGA; K-glutaminase; GAM; GAC; glutaminase C; L-glutamine amidohydrolase	WB, ICC/IF, IP	Human, Mouse, Rat
	Glutaminase Antibody (YA406) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Glutaminase.

HY-P80690A

	Glutaminase Antibody (YA406)(PBS only) glutaminase kidney isoform; GLS; GLS1; KGA; K-glutaminase; GAM; GAC; glutaminase C; L-glutamine amidohydrolase	WB, ICC/IF, IP	Human, Mouse, Rat
	Glutaminase Antibody (YA406) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Glutaminase.

HY-P86596

	Glutaminase Antibody (YA6288)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Glutaminase Antibody (YA6288) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Glutaminase.

HY-P81600

	TAX1BP3 Antibody (YA1345) glutaminase interacting protein 3; Tax interaction protein 1; Tax1 binding protein 3; Tax1bp3; TIP1	WB, IHC-P, FC	Human, Mouse, Rat
	TAX1BP3 Antibody (YA1345) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to TAX1BP3.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Targets Recommended: Glutaminase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0390G

L-Glutamine	mTOR NF-κB STAT HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
L-Glutamine GMP is L-Glutamine (HY-N0390) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na ⁺-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

glutaminase

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Antibodies

GMP Molecules

Natural
Products